Adagene Inc (ADAG)

[StockLogistics]

Results not good: 2 out of 26 success rate

“ -- Antitumor Activity in Cold Tumors: With 18 cycles of treatment at 1 mg/kg, an ovarian cancer patient experienced significant, continued reduction of an established ovarian cancer biomarker, CA125, dropping 90% to within the normal range for full clinical benefit. As of cycle 16, the patient experienced a 22% decrease in target lesions. Previously, this patient had surgery and five prior lines of systemic therapies. At the data cut-off of August 17, 2022, the disease control rate was 39% (9/23 evaluable patients).”

Lipstick on a pig (poster), so far. While it is great that one person got better and safety profile was great, A 1/26 success rate (what they call their case study) isn’t good enough imo. From March until August 17 the disease was controlled in 9/23 patients, not good enough yet imo with only one or two reductions in tumors out of all the dosed patients.